What changed from existing technology?
This study looked at how often cancer patients in northern Tanzania develop antibodies against red blood cells after receiving blood transfusions, and what factors might be linked to this problem.
This is the first study to investigate red blood cell alloimmunization in cancer patients in Tanzania, providing new data on this topic in the region.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 2
oimmunization in single and multiple transfused cancer patients and its associated factors in northern Tanzania. Cancer patients frequently require blood tran
Title ↗ABO and RhD antigens, while data on alloimmunization remain limited. The present study evaluated the prevalence of red blood cell alloimmunization in si
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
The findings may help improve blood transfusion practices in Tanzania by identifying patients at risk of alloimmunization and guiding compatible blood selection.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.